BÜHLMANN has been the market leading provider of faecal calprotectin assays in the UK for over 10 years, holding a significant portion of the market share, as recorded on the National External Quality Assurance Scheme (NEQAS). The BÜHLMANN results are split across the two main laboratory assays: fCAL ELISA and fCAL turbo assays. There is
The #1 Resource for Calprotectin in the UK and Eire
- [email protected]
- +44 (0) 23 8048 3000
Author: Webmaster
This article from the Mid and South Essex NHS Foundation Trust discusses the recent implementation of the BÜHLMANN IBDoc® Calprotectin Home Test within their Trust. You can also read about this implementation in our latest issue of Perspective. We talked to some of the key team members about their focus on introducing new technologies to
We are pleased to announce the launch of the new Calprotectin Community Support Forum! We hope the forum topics will provide you with helpful information during the current situation, and allow you to share and discuss your tips and experiences with fellow members of the Calprotectin Community. During these unprecedented times communication and support is
Faecal calprotectin (FC) is now part of the new official European Crohn’s and Colitis Organisation (ECCO) and the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) guidelines.
The New Faecal Calprotectin Care Pathway, developed by Dr James Turvill, Consultant Gastroenterologist at York Teaching Hospitals NHS Foundation Trust, and implemented by the Yorkshire and Humber AHSN, supports the implementation of NICE guidance DG11, for the detection of inflammation in the bowel (i.e. IBS vs IBD). The innovative and sensitive pathway based will help
A report from BIVDA and Innovate UK has identified that wider use of some IVD tests could save money and improve patient care. As we celebrate the 70th anniversary of the NHS is this one way to strengthen its future? Calprotectin is one of the tests identified in the report. It is already utilised in the NHS,
Calprotectin Testing Goes Mobile With advances in technology and the ubiquitous use of mobile devices, a huge opportunity has arisen to change the way some healthcare services are provided. This is especially applicable to the management of chronic conditions. With most people owning a mobile device or tablet this becomes a convenient way for patients to
On 4th December 2017 the National Institute for Health and Care Excellence issued a Medtech Innovation Briefing [MIB132]: ‘Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease’. This describes the innovative aspect that test results can be acted on more quickly than waiting for standard laboratory tests and could help reduce colonoscopies and clinical appointments. Costs may
